“Phytocannabinoids, unique secondary metabolites of the plant Cannabis sativa L., are characterised by a wide spectrum of pharmacological activities and their use in medicine and food industry has increased exponentially in recent years.

In this study, the bioavailability of 10 representatives of neutral cannabinoids and cannabinoid acids was evaluated using an in vitro model of Caco-2 cells, as well as in vivo using an inbred mouse model. In the context of a possible increase in bioavailability, the influence of matrix components associated with the ‘cannabis synergy’ phenomenon was also investigated. The analysis of cannabinoids and non-cannabinoid matrix components was performed using a sensitive and validated method based on ultra-high performance liquid chromatography coupled with high-resolution tandem mass spectrometry (UHPLC-HRMS/MS). As a proof of concept for testing formulation effects on bioavailability, the most abundant cannabinoid and its corresponding acid (CBD and CBDA) were encapsulated in nanomicelles and the effect of the formulation was tested both in vitro and in vivo.

The experiments showed that cannabidiolic acid (CBDA) had a significantly better bioavailability compared to cannabidiol (CBD), especially in the in vivo model (CBDA concentrations in mouse plasma were approximately two orders of magnitude higher than those of CBD under the same dosing conditions).

These results demonstrate the great potential of CBDA as a previously overlooked and therapeutically underutilized substance.”

https://pubmed.ncbi.nlm.nih.gov/40858181/

https://www.sciencedirect.com/science/article/abs/pii/S0378517325009470?via%3Dihub